

ASX ANNOUNCEMENT

10 August 2021

CLEANSING NOTICE

On 9 August 2021, Anteris Technologies Ltd (ASX: AVR) (**Anteris** or the **Company**) issued 1,125,000 fully paid ordinary shares (**New Shares**) to various institutional and sophisticated investors at an issue price of \$8.00 per New Share, raising approximately \$9M before issue costs. The funds raised will be utilised for general working capital as well as to undertake research and development related to the Transcatheter Aortic Valve Replacement (**TAVR**) project.

Details of the securities issued

Class of securities:	Fully paid ordinary shares
ASX code:	AVR
Date of the issue:	9 August 2021
Total number of securities issued:	1,125,000

Anteris gives notice under section 708A(5)(e) of the *Corporations Act 2001* (Cth) (the **Corporations Act**) that:

1. the New Shares have been issued without disclosure to investors under Part 6D.2 of the Corporations Act;
2. as at the date of this notice, the Company has complied with:
 - (a) the provisions of Chapter 2M of the Corporations Act as they apply to the Company; and
 - (b) section 674 of the Corporations Act;
3. as at the date of this notice, Anteris advises that it is in current ongoing discussions with a number of companies in the medical technology and pharmaceutical sectors with a view to potentially entering into new partnerships, alliances and/or strategic transactions however it has not entered into any binding agreement with any party and there is no guarantee any partnership, alliance or transaction will be entered into; and
4. apart from the matters noted above, there is no other 'excluded information' of the type referred to in sections 708A(7) and 708A(8) of the Corporations Act which is required to be disclosed by Anteris under section 708A(6)(e) of the Corporations Act.

ENDS

Anteris Technologies Ltd Registered Office:

Toowong Tower, Suite 302, Level 3, 9 Sherwood Rd, Toowong, Queensland, 4066

Customer Service

T +61 1300 550 310 | F +61 1300 972 437 | E info@anteristech.com | W anteristech.com

Brisbane • Minneapolis • Geneva • Malaga



About Anteris Technologies Ltd (ASX: AVR)

Anteris Technologies Ltd is a structural heart company delivering clinically superior and durable solutions through better science and better design. Its focus is on developing next generation technologies that help healthcare professionals create life-changing outcomes for patients.

The Anteris DurAVR™ aortic replacement valve addresses the acute need in terms of superior hemodynamic profile as well as chronic needs in its ability to sustain that profile longer over the lifetime of the patient.

The proven benefits of its ADAPT® tissue technology, paired with DurAVR™'s unique 3D single-piece aortic valve design, has the potential to deliver a functional cure to aortic stenosis patients and provide a much-needed solution to the challenges facing heart surgeons today.

Authorisation and Additional information

This announcement was authorised by the Board of Directors.

For more information:

Trina Raymond
WE Communications
E: WE-AUAnterisTech@we-worldwide.com
P: +61 420 316 449
www.anteristech.com
Twitter: @AnterisTech
Facebook: www.facebook.com/AnterisTech